|
1
|
Ishiguro H, Kimura M and Takeyama H: Role
of microRNAs in gastric cancer. World J Gastroenterol.
20:5694–5699. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kuo CY, Chao Y and Li CP: Update on
treatment of gastric cancer. J Chin Med Assoc. 77:345–353. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Piazuelo MB and Correa P: Gastric cáncer:
Overview. Colomb Med (Cali). 44:192–201. 2013.
|
|
4
|
Pasechnikov V, Chukov S, Fedorov E,
Kikuste I and Leja M: Gastric cancer: Prevention, screening and
early diagnosis. World J Gastroenterol. 20:13842–13862. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wright CM, Dan T, Dicker AP and Simone NL:
microRNAs: The Short Link between Cancer and RT-Induced DNA Damage
Response. Front Oncol. 4:1332014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang L, Xu Z, Xu X, Zhang B, Wu H, Wang
M, Zhang X, Yang T, Cai J, Yan Y, et al: SALL4, a novel marker for
human gastric carcinogenesis and metastasis. Oncogene.
33:5491–5500. 2014. View Article : Google Scholar
|
|
8
|
Xia J, Guo X, Yan J and Deng K: The role
of miR-148a in gastric cancer. J Cancer Res Clin Oncol.
140:1451–1456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim K, Lee HC, Park JL, Kim M, Kim SY, Noh
SM, Song KS, Kim JC and Kim YS: Epigenetic regulation of
microRNA-10b and targeting of oncogenic MAPRE1 in gastric cancer.
Epigenetics. 6:740–751. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li X, Wang F and Qi Y: MiR-126 inhibits
the invasion of gastric cancer cell in part by targeting Crk. Eur
Rev Med Pharmacol Sci. 18:2031–2037. 2014.PubMed/NCBI
|
|
11
|
Takagi T, Iio A, Nakagawa Y, Naoe T,
Tanigawa N and Akao Y: Decreased expression of microRNA-143 and
-145 in human gastric cancers. Oncology. 77:12–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sacconi A, Biagioni F, Canu V, Mori F, Di
Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM,
Germoni S, et al: miR-204 targets Bcl-2 expression and enhances
responsiveness of gastric cancer. Cell Death Dis. 3:e4232012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S,
Guo X, Wang B, Gang Y, Zhang Y, et al: MiR-218 inhibits invasion
and metastasis of gastric cancer by targeting the Robo1 receptor.
PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z,
Chen Z, Qiu F, Xu J and Huang J: miRNA-27b targets vascular
endothelial growth factor C to inhibit tumor progression and
angiogenesis in colorectal cancer. PLoS One. 8:e606872013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wan L, Zhang L, Fan K and Wang J: MiR-27b
targets LIMK1 to inhibit growth and invasion of NSCLC cells. Mol
Cell Biochem. 390:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin L, Wessely O, Marcusson EG, Ivan C,
Calin GA and Alahari SK: Prooncogenic factors miR-23b and miR-27b
are regulated by Her2/Neu, EGF, and TNFα in breast cancer. Cancer
Res. 73:2884–2896. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Z, Liu S, Shi R and Zhao G: miR-27
promotes human gastric cancer cell metastasis by inducing
epithelial-to-mesenchymal transition. Cancer Genet. 204:486–491.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin CH, Lin PP, Lin CY, Huang CH, Huang YJ
and Lane HY: Decreased mRNA expression for the two subunits of
system xc-, SLC3A2 and SLC7A11, in WBC in patients with
schizophrenia: Evidence in support of the hypo-glutamatergic
hypothesis of schizophrenia. J Psychiatr Res. 72:58–63. 2015.
View Article : Google Scholar
|
|
19
|
Yim DG, Ghosh S, Guy GR and Virshup DM:
Casein kinase 1 regulates Sprouty2 in FGF-ERK signaling. Oncogene.
34:474–484. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar
|
|
21
|
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang
X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a
metastasis suppressor in gastric cancer by targeting Bcl-w and
specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar :
|
|
22
|
Guo B, Liu L, Yao J, Ma R, Chang D, Li Z,
Song T and Huang C: miR-338-3p suppresses gastric cancer
progression through a PTEN-AKT axis by targeting P-REX2a. Mol
Cancer Res. 12:313–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cabrita MA and Christofori G: Sprouty
proteins, masterminds of receptor tyrosine kinase signaling.
Angiogenesis. 11:53–62. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li P, Tao L, Yang J, Cai H, Ju X, Li J,
Shao P, Cao Q, Qin C, Meng X and Yin C: Sprouty2 is associated with
prognosis and suppresses cell proliferation and invasion in renal
cell carcinoma. Urology. 82:253 e1–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rathmanner N, Haigl B, Vanas V, Doriguzzi
A, Gsur A and Sutterlüty-Fall H: Sprouty2 but not Sprouty4 is a
potent inhibitor of cell proliferation and migration of
osteosarcoma cells. FEBS Lett. 587:2597–2605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng Y and Zhang C: MicroRNA-21 in
cardiovascular disease. J Cardiovasc Transl Res. 3:251–255. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mei Y, Bian C, Li J, Du Z, Zhou H, Yang Z
and Zhao RC: miR-21 modulates the ERK-MAPK signaling pathway by
regulating SPRY2 expression during human mesenchymal stem cell
differentiation. J Cell Biochem. 114:1374–1384. 2013. View Article : Google Scholar
|
|
28
|
Kwak HJ, Kim YJ, Chun KR, Woo YM, Park SJ,
Jeong JA, Jo SH, Kim TH, Min HS, Chae JS, et al: Downregulation of
Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene.
30:2433–2442. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Biyashev D, Veliceasa D, Topczewski J,
Topczewska JM, Mizgirev I, Vinokour E, Reddi AL, Licht JD, Revskoy
SY and Volpert OV: miR-27b controls venous specification and tip
cell fate. Blood. 119:2679–2687. 2012. View Article : Google Scholar :
|
|
30
|
Wang C, Delogu S, Ho C, Lee SA, Gui B,
Jiang L, Ladu S, Cigliano A, Dombrowski F, Evert M, et al:
Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis
via activation of MAPK and PKM2 pathways. J Hepatol. 57:577–583.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu G, Qin XQ, Guo JJ, Li TY and Chen JH:
AKT/ERK activation is associated with gastric cancer cell
resistance to paclitaxel. Int J Clin Exp Pathol. 7:1449–1458.
2014.PubMed/NCBI
|
